Healthcare is the largest industry in the United States, and yet total medical expenses continue to grow unabated almost twice as fast as GDP, driven in part by aging baby-boomer demographic trends and advances in medical technology. The industry is widely acknowledged to be unsustainable in its current form: It costs too much and is unaffordable for too many, it is notoriously inefficient, and it is riddled with quality and service problems. Few stakeholders – patients, physicians, hospitals or payers – are happy with the status quo. The industry is under tremendous economic, regulatory and social pressure to improve, and as a result, is in the midst of the most fundamental transformation since it shifted from indemnity to managed care in the late 1980’s.

Within this dynamic environment, Santé makes selective early-stage venture investments in innovative new companies with the potential to improve healthcare quality, efficiency or access.

  • Back exceptional entrepreneurs and executives
    We believe there is no better single predictor of success than the caliber and experience of the team associated with an opportunity. As such, we start with the team and develop lasting partnerships with truly exceptional people.
  • Focus exclusively on healthcare
    By maintaining a narrow and specialized investment focus within this dynamic industry, Santé is better able to bring the deep domain expertise; complementary operational, clinical, regulatory and investory perspectives; and extensive network of industry contacts necessary to build valuable, enduring healthcare companies.
  • Partner with leading healthcare providers
    Limited partner investors in Santé include some of the largest health delivery systems in the country, and collectively aggregate billions of dollars of healthcare spend, thousands of physicians and dozens of hospitals. These strategic investors allow Santé to provide its portfolio companies with superior market insight, strategy formulation, due diligence resources, business development opportunities and potential co-investment partners.
March 18, 2020 NewLink Genetics Stockholders Approve Merger with Lumos Pharma
Read More
February 25, 2020 BioStable Science & Engineering Announces Initial Closing of Series C Equity Round
Read More